Video Clips
Quoted moments from Alaska public meetings, hearings, and press conferences.

Dan Sullivan campaign: Senator Sullivan’s Election Night Speech ·

Dan Sullivan campaign: Senator Sullivan’s Election Night Speech ·

Dan Sullivan campaign: Senator Sullivan’s Election Night Speech ·

Dan Sullivan campaign: Senator Sullivan’s Election Night Speech ·

Senate Indian Affairs (Murkowski): Business meeting to consider S.239, to take certain mineral interests into trust for the benefit of the Crow Tribe of Montana, S.1055, to amend the Indian Health Care Improvement Act to modify the notification requirement for emergency contract health services for certain beneficiaries, S.1514, to take certain land in the State of Washington into trust for the benefit of the Quinault Indian Nation, S.3219, to transfer certain Federal land into trust for certain Indian Pueblos in the State of New Mexico, and H.R.2400, to take certain Federal land in the State of California into trust for the benefit of the Pit River Tribe. ·

Senate Indian Affairs (Murkowski): Business meeting to consider S.239, to take certain mineral interests into trust for the benefit of the Crow Tribe of Montana, S.1055, to amend the Indian Health Care Improvement Act to modify the notification requirement for emergency contract health services for certain beneficiaries, S.1514, to take certain land in the State of Washington into trust for the benefit of the Quinault Indian Nation, S.3219, to transfer certain Federal land into trust for certain Indian Pueblos in the State of New Mexico, and H.R.2400, to take certain Federal land in the State of California into trust for the benefit of the Pit River Tribe. ·

Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Glenn Graham
“No, in fact, Senator, I can't, particularly given the accomplishments of VA. I think this comes at a very bad time. It's already been alluded that other federal sources of funding, including NIH, are facing great uncertainties now. VA research being a constant, you know, reliable source of support for research helping veterans certainly would be, would be very welcome.”Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Glenn Graham
“I think people in the VA by large, at least those that I work with, were dedicated civil servants. They felt that federal service was an honor and a privilege and a duty to veterans. But yet somehow the federal civil servants, even including in the VA, were treated somehow as a public enemy. And that created a hostile work environment that I did not understand.”Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Glenn Graham
“I was struck by the fact that people who had gone through the entire recruitment process up to basically signing on would sometimes decline jobs. I tried to get a specific percentage of that, it's hard to know. Although one media source said that early in the first part of 2025, there were about 40% of jobs offered to physicians in the VA were declined.”Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Senate Veterans' Affairs (Sullivan): Hearings to examine advancing the mission, focusing on evaluating the future of VA research. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Energy and Natural Resources (Murkowski): An oversight hearing to examine the Federal Regulatory Commission. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Senate Health, Education, Labor, and Pensions (Murkowski): Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care. ·

Douglas Schiess
“The threat China poses is real.”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“the portfolio acquisition executives is trying to take all of the things that the SDA did correct and put those in all of the PAEs, and so, you know, Secretary Mink talks about giving 90% of contracting to them, and so what I would say to you, if confirmed, I promise you to continue to work that so that all of our PAEs take some of that capability to bring on fast systems”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“we did have large folks that took the DRP and other programs. And so that, that was a significant cut to us. But we are working to bring those back. As a matter of fact, Space Systems Command is trying to hire 100 civilians a month”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“The People's Liberation Army has rapidly expanded its space capabilities and is fielding systems designed both to exploit space for intelligence, surveillance, and reconnaissance, and to deny U.S. ability to use space capabilities in a crisis or a conflict.”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“in our request, we also asked for an additional 2,000 civilians.”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“they are using their intelligence surveillance and reconnaissance efforts to target our forces much farther than they ever have in the past. They've built a kill chain to be able to see our carrier strike groups, our bombers at much farther, pace, speed, and distances, and they've also developed missiles and weapon systems to go after that.”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“weapon systems, facilities, uh, training capability, all of those things are in there. We are requesting an increase in Guardians, 2,800 personnel, but it is mostly equipment.”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“the $71.1 billion that the president has asked for is exactly what we need in a couple areas in there.”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“we need the ability to have space superiority, and what that means is we have to have the ability to counter someone else's ability to, to hold our satellites at risk and to be able to destroy them. And the vast bulk of that money is for, is for equipment, not, not personnel.”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Douglas Schiess
“what they are doing with what I'll call counter-space and space superiority capabilities is breathtakingly fast. They have watched the Space Force and the Air Force before that and the activities that we have had to enable the joint force, and they have determined that they need to come up with capabilities to do that. So we've seen anti-satellite tests from the ground. There are capabilities in space that hold our satellites at risk, and they continue to do that at a rapid pace.”Senate Armed Services (Sullivan): Hearings to examine the nomination of Lieutenant General Douglas A. Schiess, USSF, to be general and Chief of Space Operations. ·

Keith Sonderling
“I would rely and have relied on the career ethics officials at the Office of Government Ethics to make that.”Senate Health, Education, Labor, and Pensions (Murkowski): Hearings to examine the nomination of Keith Sonderling, of Florida, to be Secretary of Labor. ·